Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-Seq of CD138-positive cells

ABSTRACT: RNA-Seq of CD138-positive cells purified from bone marrow samples

PROVIDER: PRJEB36223 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR4134070_1.fastq.gz	Fastqsanger.gz
	ERR4134070_2.fastq.gz	Fastqsanger.gz
	ERR4134080_1.fastq.gz	Fastqsanger.gz
	ERR4134080_2.fastq.gz	Fastqsanger.gz
	ERR4134090_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 1756

Similar Datasets

RNA-Seq of CD138-positive cells

Project description:RNA-Seq of CD138-positive cells purified from bone marrow samples

| PRJEB37100 | ENA

Transcription profiling by array of human CD138 purified bone marrow plasma cells from relapsed multiple myeloma patients

Project description:Gene expression profiling of CD138 purified bone marrow plasma cells of relapsed multiple myeloma patients

2017-02-09 | E-MTAB-4715 | biostudies-arrayexpress

Transcription profiling by array of human CD138 purified bone marrow plasma cells from patients with multiple myeloma

Project description:Gene expression profiling of CD138 purified bone marrow plasma cells of previously untreated multiple myeloma patients

2017-02-09 | E-MTAB-4717 | biostudies-arrayexpress

Transcription profiling by array of human CD138 purified bone marrow plasma cells from patients with smoldering multiple myeloma

Project description:Gene expression profiling of CD138 purified bone marrow plasma cells of patients with smoldering multiple myeloma

2023-05-31 | E-MTAB-4743 | biostudies-arrayexpress

Gene expression analysis between CD20- CD138- and CD20+ CD138+ subpopulations using sorted MWCL-1

Project description:For the complete cure of tumors, it is essential to eliminate cancer-initiating cells (CICs). Immunohistochemically, most tumor cells were CD20 and/or CD138 positive in clinical samples of lymphoplasmacytic lymphoma (LPL), and CD20- CD138- cells were hardly detected. Therefore, useful positive markers expressing in a candidate of CICs of LPL are necessary. First, we performed gene expression microarray analysis between CD20- CD138- and CD20+ CD138+ subpopulations using sorted Waldenstrom macroglobulinemia cell line (MWCL-1).

2016-02-17 | GSE73756 | GEO

Transcription profiling by array of human CD138 purified bome marrow plasma cells from patients with mutliple myeloma or monoclonal gammopathy of unknown significance

Project description:Gene expression profiling of CD138 purified bone marrow plasma cells of previously untreated multiple myeloma patients and individual with monoclonal gammopathy of unknown significance (MGUS)

2010-08-09 | E-MTAB-317 | biostudies-arrayexpress

Expression data from CD138+ cells obtained from MM patients at diagnosis

Project description:Thalidomide-dexamethasone (TD) combination is an effective induction therapy for newly diagnosed multiple myeloma patients, candidates for subsequent autologous stem cell transplantation (ASCT). Since maximization of tumor response before ASCT may favorably affect the clinical outcomes, we designed a study to identify a gene expression profile (GEP) signature predictive of attainment of complete response to TD induction therapy. CD138+ bone marrow samples obtained at diagnosis from 112/311 patients were analyzed. Two subsequent time phases were planned. Firstly, a GEP supervised analysis, performed on a training set of 32 patients, allowed to identify 157 probe sets differentially expressed in complete responder + near complete responder (CR+nCR) versus ?partial responder patients. Than, we generated an 8-gene GEP signature predicting at diagnosis the probability to achieve CR+nCR to TD induction therapy. The performance of this assay was subsequently validated in an 80 patients training set. The 8-gene signature provide a negative predictive value of 93% and a positive predictive value of 44%. The 8 genes were down-regulated in patients who achieved at least a nCR. These results could be an important first step to adopting a diagnostic assay, used to determine, at diagnosis, patients who will respond more favourably to a particular treatment strategy. This series of microarray experiments contains the gene expression profiles of purified plasma cells (PCs) obtained from 32 newly diagnosed multiple myeloma (MM). PCs were purified from bone marrow specimens, using CD138 immunomagnetic microbeads. The purity of the positively selected PCs was assessed by flow cytometry and was > 90% in all cases. 5 micrograms of total RNA was processed and hybridized to the Affymetrix HG U133 Plus 2.0 GeneChip following the manufacturer's instructions.

2013-06-01 | E-GEOD-16791 | biostudies-arrayexpress

Transcription profiling by array of human CD138 purified bone marrow plasma cells, CD27 memory B-cells, polyclonal plasmablastic cells and human myeloma cell lines

Project description:Gene expression profiling of CD138 purified bone marrow plasma cells of healthy donors, CD27 memory B-cells, cultured ployclonal plasmablastic cells and cultured human myeloma cell lines. Samples from healthy donors have been re-used from ArrayExpress experiment E-MEXP-2360. Some of the myeloma cell line samples have been re-used from E-TABM-937 and E-TABM-1088.

2017-02-23 | E-MTAB-5212 | biostudies-arrayexpress

Transcription profiling by array of human CD138 purified bone marrow plasma cells of previously untreated multiple myeloma patients and individuals with monoclonal gammopathy of unknown significance (MGUS)

Project description:Gene expression profiling of CD138 purified bone marrow plasma cells of previoulsy untreated multiple myeloma patients and individual with monoclonal gammopathy of unknown significance (MGUS)

2010-10-09 | E-MTAB-316 | biostudies-arrayexpress

Gene expression analysis between CD20- CD138- and CD20+ CD138+ subpopulations using sorted MWCL-1

2016-02-17 | E-GEOD-73756 | biostudies-arrayexpress